Amgen: Q4 beats consensus

(CercleFinance.com) - The biopharmaceutical laboratory Amgen has published adjusted Q4 2019 EPS that is up 6% at 3.
64 dollars, which is about 25 cents above the market consensus, with adjusted operating profit down 4% at 2.6 billion dollars.

The corresponding margin thus contracted by 0.7 point to 44.6% for revenues which fell by 1% to 6.2 billion dollars, which still reflected the impact of competition from bio-similars and generic against key products.

Reporting FY 2019 adjusted EPS that is up 3% at 14.82 dollars, hence well above its target range set three months ago (14.20-14.45 dollars), the company now expects 14.85-15.60 dollars in FY 2020.


Copyright (c) 2020 CercleFinance.com. All rights reserved.